Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
Crohn’s and Colitis 2025 Advance Access: 13 July 2025 Doi: 10.1093/ecco-jcc/jjaf124
Mirikizumab was evaluated for its ability to achieve disease clearance (DC) across two years in adults with moderately to severely active ulcerative colitis within the LUCENT trial programme. DC required concurrent symptomatic, endoscopic, and histologic remission.